524403
Pravastatin, Sodium Salt
A water-soluble, competitive 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that potently blocks in vivo cholesterol synthesis (Ki = ~1 nM).
别名:
Pravastatin, Sodium Salt, (βR,δR,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-Hexahydro-β,δ,6-trihydroxy-2-methyl-8[(2S)-2-methyl-1-oxobutoxyl]-1-naphthaleneheptanoic Acid Na, 3β-Hydroxycompactin, Na
登录查看公司和协议定价
所有图片(1)
About This Item
推荐产品
品質等級
化驗
≥98% (HPLC)
形狀
crystalline solid
製造商/商標名
Calbiochem®
儲存條件
OK to freeze
desiccated (hygroscopic)
顏色
white
溶解度
water: 100 mg/mL
運輸包裝
ambient
儲存溫度
2-8°C
InChI
1S/C23H36O7.Na/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28;/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28);/q;+1/p-1/t13-,14-,16+,17+,18+,19-,20-,22-;/m0./s1
InChI 密鑰
VWBQYTRBTXKKOG-IYNICTALSA-M
一般說明
A water-soluble, competitive 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that blocks in vivo cholesterol synthesis (Ki ~1 nM). Also acts as an immunomodulator and an inhibitor of ras p21 isoprenylation.
A water-soluble, competitive 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that potently blocks in vivo cholesterol synthesis (Ki = ~1 nM). Offers cardioprotection. Also acts as an immunomodulator and an inhibitor of ras p21 isoprenylation.
生化/生理作用
Cell permeable: no
Primary Target
AMG-CoA reductase
AMG-CoA reductase
Product does not compete with ATP.
Reversible: no
Target Ki: ~1 nM inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and blocking in vivo cholesterol synthesis
包裝
Packaged under inert gas
警告
Toxicity: Environmental Hazard (N)
重構
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
其他說明
Due to the nature of the Hazardous Materials in this shipment, additional shipping charges may be applied to your order. Certain sizes may be exempt from the additional hazardous materials shipping charges. Please contact your local sales office for more information regarding these charges.
Kwak, B., et al. 2000. Natl. Med.6, 1399.
Hamelin, B.A., and Turgeon, J., 1998. Trends Pharmacol. Sci.19, 26.
Narisawa, T., et al. 1996. Jpn. J. Cancer Res.87, 798.
Cohen, L.H., et al. 1993. Biochem. Pharmacol.45, 2203.
Koga, T., et al. 1990. Biochim. Biophys. Acta.1045, 115.
Yoshino, G., et al. 1986. Diabetes Res. Clin. Pract. 2, 179
Hamelin, B.A., and Turgeon, J., 1998. Trends Pharmacol. Sci.19, 26.
Narisawa, T., et al. 1996. Jpn. J. Cancer Res.87, 798.
Cohen, L.H., et al. 1993. Biochem. Pharmacol.45, 2203.
Koga, T., et al. 1990. Biochim. Biophys. Acta.1045, 115.
Yoshino, G., et al. 1986. Diabetes Res. Clin. Pract. 2, 179
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
11 - Combustible Solids
水污染物質分類(WGK)
WGK 2
閃點(°F)
Not applicable
閃點(°C)
Not applicable
其他客户在看
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门